MedTrace Logo

Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.

NCT00408473 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2022-02-07

No results posted yet for this study

Summary

The purpose of the study is to assess the efficacy of flecainide controlled release (CR) in the prevention of recurrent AF during 9 months of active treatment compared to placebo in patients with only one documented AF episode.

Conditions

Interventions

DRUG

Flecainide

Sponsors & Collaborators

  • 3M

    collaborator INDUSTRY

  • MEDA Pharma GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Prof E Aliot · CHU Brabois, avenue de Bourgogne, 54511 Vandoeuvre-les-Nancy. FRANCE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Belgium
  • Bulgaria
  • France
  • Germany
  • Netherlands
  • Romania
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408473 on ClinicalTrials.gov